Co-infection and Cancer (R01 Clinical Trial Not Allowed)
Investigating co-infection effects on cancer causation, particularly in novel prevention strategies for understudied populations, excluding HIV co-infection.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision) | June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | Expires January 8, 2026
Funding Amounts: No budget cap; budgets must reflect actual project needs. Project period up to 5 years.
Summary: Supports mechanistic and epidemiologic research on the roles of co-infection (excluding HIV) in cancer causation, prevention, and treatment, with emphasis on novel opportunities and understudied populations.
Key Information: Clinical trials are not allowed; applications focused solely on HIV co-infection or a single pathogen are not responsive.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, aims to advance mechanistic and epidemiologic research into how co-infections contribute to cancer risk, progression, and disparities. Co-infection is defined as infection by two or more infectious agents (pathogenic or non-pathogenic), either concurrently or sequentially, and includes both acute and chronic infections by viruses, bacteria, parasites, and other microorganisms. The program encourages studies that can inform new prevention or treatment strategies, especially in understudied or high-burden populations.
Preference is given to research on co-infections involving known or suspected oncogenic agents (excluding HIV), and to projects that may reveal novel opportunities for cancer prevention or intervention. Both U.S. and international research settings are eligible, and multidisciplinary, collaborative, and diverse population studies are encouraged.
